Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Down 97.6% in February

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a significant drop in short interest in the month of February. As of February 13th, there was short interest totaling 610 shares, a drop of 97.6% from the January 29th total of 24,900 shares. Based on an average daily volume of 7,063 shares, the short-interest ratio is presently 0.1 days. Approximately 0.4% of the shares of the stock are sold short. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 7,063 shares, the short-interest ratio is presently 0.1 days.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

THNR traded down $0.14 on Wednesday, hitting $26.00. 1,182 shares of the company were exchanged, compared to its average volume of 3,583. The business’s fifty day moving average is $26.03 and its 200 day moving average is $24.64. Amplify Weight Loss Drug & Treatment ETF has a fifty-two week low of $18.56 and a fifty-two week high of $27.28. The firm has a market capitalization of $3.90 million, a P/E ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The company also recently declared an annual dividend, which was paid on Wednesday, December 31st. Investors of record on Tuesday, December 30th were issued a $0.4132 dividend. The ex-dividend date was Tuesday, December 30th. This represents a dividend yield of 162.0%.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC boosted its position in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the quarter. Jane Street Group LLC owned approximately 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.